of ESCRT-III signal residing beyond the plane of the plasma membrane, we visualized the plasma membrane using a lipidated fluorescent probe. PSCFP2-CHMP2A signal was observed in discrete distributions extending away from the cytosol and beyond the membrane plane in Gag-expressing cells (Fig. 2C ). Co-clusters of HIV Gag and PSCFP2-CHMP2A were confirmed with scanning electron microscopy (SEM) to be membrane-budding structures resembling virus-like particles (Fig. 2E) . We further confirmed our observations of ESCRT-III localization to the HIV Gag interior using immunogold transmission electron microscopy ( fig. S7 ).
To facilitate a robust statistical analysis of ESCRT organization at HIV assembly sites, we performed two-color single-particle averaging. The resulting probability distributions of PSCFP2-ESCRT probes and HIV Gag revealed significant signal from each ESCRT subunit within the interior of the viral lattice (Fig. 3 , A to C; fig. S8 ; and supplementary text). Radially averaged probability density plots of HIV Gag and ESCRT probes revealed 92% of PSCFP2-Tsg101, 61% of PSCFP2-CHMP4B, 80% of PSCFP2-CHMP2A, and 78% of PSCFP2-Vps4A integrated probability residing within the estimated radius of the HIV Gag shell (Fig. 3E ). This analysis highlighted a pool of PSCFP2-CHMP4B residing beyond the HIV Gag lattice (39% remaining probability), potentially indicating a signature of ESCRT-III polymer extending toward the neck of the budding structure. As a control, we observed an order of magnitude less PSCFP2-CHMP4B signal residing within the probability shell of mutant Gag particles, unable to recruit ESCRT-I (Gag DPTAP ) (1, 2) , as compared with wild-type Gag (Fig. 3, D and E). This suggests that the Gag PTAP motif is required for localizing ESCRT-III subunits to the particle interior. These results support our singleparticle observations and highlight a distinct scaffolding mechanism of ESCRT-III and Vps4A subunits within the interior of the Gag lattice.
The presence of ESCRT-III subunits within the Gag lattice suggests that a portion of this pool may become trapped within the viral particle while mediating bud neck constriction and abscission. To test this possibility, we purified virus-like particles (VLPs) from GFP-ESCRT-expressing cells and performed quantitative fluorescence microscopy (Fig. 4A ). Using HIV Gag-GFP as a molecular standard, we estimated that on average hundreds of copies of GFP-ESCRT probes reside within released particles. Qualitative coincidence detection between Gag-mCherry and GFP-ESCRT proteins showed that GFP-ESCRT probes were detected in the majority of released particles (50 to 90%) ( fig. S9 ). Correlative two-color iPALM and SEM imaging confirmed the presence of ESCRT probes within released VLPs (Fig. 4B) . Western blot analysis showed that GFP-Tsg101 and GFP-CHMP4B were readily detected in purified VLP fractions (Fig. 4C) . Levels of GFP-CHMP2A, but not GFP-CHMP4B or GFP-Tsg101, were reduced in released virus particles relative to membrane-associated particles (Fig. 3, A to C) . This suggested that CHMP2A subunits may undergo selective remodeling upon virus abscission. This may be mediated by the ATPase activity of Vps4, given the established interaction between Vps4 and CHMP2A (17) .
Current models have been unable to distinguish whether ESCRTs localize to the base of the neck of a virion (in trans) or to the head of the virion (in cis) in order to constrict and release the viral particle from the plasma membrane. Our results show that ESCRT-III and Vps4A probes concentrate on the interior of the HIV Gag lattice and occupy a similar volume to that of ESCRT-I. This architecture is consistent with previous cytokinesis observations that ESCRT-III subunits initiate proximal to the midbody scaffold protein CEP55 and ESCRT-I (12). Indeed, HIV Gag and CEP55 share features, such as dual Tsg101 and ALIX recruitment domains (18) (19) (20) , as well as an apparent independence of ESCRT-II for mediating membrane abscission (19) (20) (21) . Collectively, these observations suggest that structural proteins, such as HIV Gag and CEP55, act to nucleate structures composed of ESCRT-I, ESCRT-III, and Vps4 subunits (supplementary text). These subunits then serve as distinct templates (acting in cis relative to the structural scaffold) for ESCRT-III polymerization and Vps4-mediated disassembly/remodeling of CHMP2A, ultimately leading to membrane abscission (Fig. 4C) . Further studies will be required to dissect the interplay between scaffolding and polymerizing/depolymerizing pools of ESCRT-III and the role this dynamism plays in mediating viral membrane constriction and abscission. of sustained replication in which the replicating microbe induces proliferation and selection of members of the replicating B cell repertoire. In this regard, we investigated mycoplasma infection because it has the features of chronicity (7) and, as an obligatory parasite, is largely confined to the surface of cells (8, 9) . In the course of our experiments, we discovered that some human mycoplasmas produce a protein that binds to immunoglobulins (Igs) with high affinity. This protein, which we refer to as Protein M, has a structure that differs from all others in the Protein Data Bank (PDB). Because we were interested in clonal B cell proliferation in the context of chronic infections, we investigated whether monoclonal antibodies produced as a result of multiple myeloma react with mycoplasma antigens. We tested the ability of plasma from 20 multiple myeloma patients (10) to bind to total cellular extracts from multiple mycoplasma species, including human pathogens or commensal organisms and others that infect nonhuman vertebrates. Remarkably, these experiments showed that the antibodies in the plasma all reacted strongly with molecules present in human, but not nonhuman, pathogenic mycoplasmas ( Fig. 1A and fig. S1A ). The main reactivity was with a protein with an apparent molecular weight of~50 kD in Mycoplasma genitalium and with several proteins with apparent molecular weights of 40 to 65 kD in Mycoplasma penetrans (Fig. 1A) . We focused our attention on the protein from M. genitalium because it appeared to be more homogeneous as determined with gel electrophoresis (Fig. 1A) . The Ig reactivity with the M. genitalium protein was similar for all patients' plasma tested (fig. S1A). To substantiate that the clonal multiple myeloma Ig is the component responsible for binding to the M. genitalium protein, as opposed to a highly reactive protein that copurifies with it, the Fab′ (fragment antigen-binding) of the primary monoclonal antibody in the plasma of multiple myeloma patient 13PL (13PL Fab′) was highly purified by chromatography followed by crystallization, and its reactivity was studied by using dissolved crystals as a source of the antibody (Fig. 1, B to D). The 13PL Fab′ from the dissolved crystals bound to the same antigen in mycoplasmas as antibodies isolated from whole sera (Fig. 1C) . To confirm that the crystals contained an antibody, the x-ray structure was determined at 1.2 Å resolution, and only a Fab′ was present (Fig. 1D ). To test whether a similar reactivity could be found in blood from nonmyeloma normal donors (fig. S1B), samples from random donors were studied. The sera from these normal donors also surprisingly reacted with the same mycoplasma proteins as did the clonal myeloma Igs, indicating that the ability of human Igs to react with this mycoplasma protein was not confined to those produced in multiple myeloma. We therefore termed the M. genitalium protein that reacts with Ig as Protein M.
A Structurally Distinct Human
At this point, the possibilities were that Protein M was an antigen to which most people make an antibody or was a protein that binds to Ig domains or other features that are present in most antibodies. To study these possibilities, we first isolated Protein M using an affinity column constructed from antibody 13PL. The affinity-purified Protein M was separated on SDSpolyacrylamide gel electrophoresis (SDS-PAGE) gels followed by Western blot analysis by using a different myeloma antibody to confirm the presence of the binding protein. . S4A ) as well as mouse, rat, rabbit, goat, and bovine IgGs (fig. S4B) . To further elucidate the minimum sequence responsible for antibody binding, the Protein M and 13PL IgG complex (mixed in a 1:1.1 molar ratio) was incubated with trypsin for 5 hours. SDS-PAGE gel analysis showed that a truncated protein remained intact after 5 hours as compared with uncomplexed Protein M, which was totally digested into smaller fragments. The trypsin-digested Protein M (Protein M TD) was found by means of mass spectroscopy to contain residues 74 to 482 (fig. S5) . (fig. S6) . Because a variety of antibodies with different complementarity-determining regions (CDRs) all bind to Protein M, specific interaction with the combining site of the antibody molecule appeared to be excluded. To understand the molecular basis for this interaction, crystal structures of recombinant Protein M TD in complex with two antibody Fabs PGT135 against HIV-1 gp120 with a k light chain (K d = 3.7 nM) (12) and Fab CR9114 against influenza hemagglutinin with a l light chain (K d = 1.9 nM) (13) were determined to 1.65 and 2.50 Å resolution, respectively (Fig. 2  and table S1 ). Although the 13PL Fab′-Protein M TD complex could not be crystallized, we were able to obtain the structure through electron microscopy, which showed a similar mode of binding ( fig. S7) (14) . Protein M TD comprises a large domain (residues 78 to 440) that includes a leucine-rich repeat (LRR)-like subdomain and a smaller domain (residues 441 to 468) ( Fig. 2A) . Protein M TD binds predominantly to the variable light (V L ) domains of both PGT135 Fab (Fig. 2B ) and CR9114 Fab (Fig. 2C) (Fig. 2D and figs. S8A and S9A ) and CR9114 Fab (Fig. 2E and figs. S8B and S9B) , respectively, mainly from the V L domains of the Fabs (15). The common interacting positions, which are about two-thirds occupied by hydrophilic residues in both antibodies, are located on one edge of V L (Fig. 2F and tables S2 and S3 ). Ten conserved hydrogen bonds and one salt bridge are . However, some of the nonpolar interactions may be conserved even with different amino acids. The N-and C-terminal fragments (residues 37 to 74 and residues 469 to 556), which were truncated in Protein M TD as compared with Protein M, are likely disordered because the three-dimensional reconstructions of a Fab in complex with Protein M and Protein M TD by using negative-stain electron microscopy are nearly identical (figs. S10 and S11).
To determine the scope of Protein M binding to antibodies with different light-chain configurations and allotypes, the K d of Protein M TD to 24 different light chains in a variety of formats were determined. Because the heavy chains potentially could alter the light-chain conformations, we studied the same germline light chain paired with three different heavy chains. The particular heavy chains made little difference, and the K d varied between 1.5 and 4.8 nM for four V H /V L combinations ( fig. S12, A to C) . Similarly, when the same heavy chain was paired with four different light chains, Protein M binding ranged from 1.8 to 2.4 nM (fig. S12, D to G) . We evaluated the effect of allotypic variation using five k chain allotypes (k1, k2, k3, k4, and k6) and three l chain allotypes (l2, l5, and l11). Allotypic variation had little effect, and the K d for the allotypic variants ranged between 1.0 and 4.8 nM ( fig. S12 and table S6 ). The preservation of binding affinity in the presence of allotypic variation is to be expected because the critical Protein M contacts are largely conserved among allotypes (tables S4 and S5). To determine whether antigen specificity affected Protein M, we determined K d for Protein M TD binding to a panel of eight affinity-matured monoclonal antibodies against the same HIV-1 gp120 antigen but with different epitopes and found that K d only varied between 0.7 and 3.8 nM (fig. S12 , Q to X, and table S6).
Last, we assessed the percentage of polyclonal human Igs from the plasma of normal blood donors that was capable of binding to Protein M. After two passages through a column containing Protein M TD immobilized on Ni-nitrilotriacetic acid matrix at a flow rate of 1 ml/min, >90% of all the Igs were removed, which is in agreement with our data that showed Protein M binds to all human monoclonal antibodies that we have tested to date.
These structural studies suggested that Protein M should preclude the ability of the antibody to bind to its antigen because it displaces or distorts the CDRs and/or may use its C-terminal domain to sterically block entrance to the antibodycombining site ( fig. S13) . We tested the ability of recombinant Protein M and Protein M TD to block antigen-antibody union for six different antigen-antibody pairs, including two polyclonal auto-antibodies. The monoclonal antibodies used were generated against human influenza virus (13), HIV-1 (16), human Ebola (17) , and mouse Ebola (18); polyclonal antibodies were purified from Goodpasture's disease patient serum (19) and lupus mouse serum (20) . Blocking of the binding of serum polyclonal antibodies to antigens by Protein M is important because such sera represents a collection of antibodies rather than a single monoclonal species. Prior incubation of the antibodies with Protein M or Protein M TD (in a 1:8 molar ratio) strongly inhibited antibody binding to its cognate antigen (Fig. 3) , but the order of addition is critical. Once antigenantibody union has occurred for high-affinity antigens, Protein M does not disrupt the antibodyantigen complex ( fig. S14 ).
This discovery, of a heretofore unknown highaffinity Ig-binding protein in human M. genitalium, should be considered in the context of other known Ig-binding proteins, such as Protein G, Protein A, and Protein L (21-23), which have been invaluable reagents and tools in the antibody field. The Protein M structure is very different from these other Ig-binding proteins and is also very www.sciencemag.org SCIENCE VOL 343 7 FEBRUARY 2014 different from any other known protein structures. Unlike Protein G, Protein A, and Protein L-which all contain multiple, small, Ig-binding domains-Protein M has a large domain of 360 residues, which binds principally to antibody V L domains, as well as a LRR-like motif (24) that faces away from the antibody molecule and may have an as-yet uncharacterized function. Protein M also contains a 115-residue C-terminal domain that likely protrudes over the antibody combining site. To our knowledge, compared with other known Ig-binding proteins, the Protein M TD-antibody Fab buried surface area is the largest (25) .
Protein M binds to antibodies with either k or l light chains using conserved hydrogen bonds and salt bridges, from backbone atoms and conserved side chains, and some conserved van der Waals interactions as well as other nonconserved interactions. These conserved interactions provide a structural basis for the broad reactivity with Fvs, Fabs, or Igs. In contrast, the primary binding site for Protein G and Protein A is the antibody Fc domain, although secondary lower-affinity binding sites include the C H 1 domain of IgG for Protein G (26) or V H of the human V H 3 gene family for Protein A (22) . Protein L binds only to the V L of most human k light chains, except for the VkII subgroup (Fig. 4 ) (23) . Thus, this new broad-scope, high-affinity antibody-binding protein, which binds both k and l chains, is likely to find a myriad of applications in immunochemistry. In addition to its general use, Protein M may be particularly important for large-scale purification of therapeutic antibodies. Last, although Protein M may be important for the host-parasite relationship, further studies are necessary to elucidate the consequences of its expression on the parasite surface. D evelopmental programs generally induce uniform or regionalized gene expression patterns to yield highly reproducible bodyplan outcomes. However, stochastic mechanisms are sometimes incorporated to diversify cell types in nervous systems. Nonautonomous stochastic mechanisms using lateral inhibition strategies have been well described, whereas cell-autonomous, stochastic mechanisms involved in color opsin and olfactory receptor selection in mammals are only partially understood (1, 2) .
The fly eye is composed of two stochastically distributed subtypes of ommatidia (unit eyes) defined by expression of specific light-detecting Rhodopsin proteins in R7 photoreceptors (PRs). The random distribution is controlled by the stochastic expression of the Per-Arnt-Sim basic helix-loophelix (PAS-bHLH) transcription factor Spineless (Ss). Ss expression in~65% of randomly distributed R7s induces "yellow" (yR7) fate and expression of Rhodopsin4 (Rh4), whereas the absence of Ss in the remaining~35% of R7s allows for "pale" (pR7) fate and Rhodopsin3 (Rh3) expression (Fig. 1, A and B) . Loss of ss function leads to the transformation of all R7s to pR7 fate and Rh3 expression ( fig. S1A ), whereas ectopic Ss causes all R7s to acquire yR7 fate and express Rh4 (fig. S1B) (1) (2) (3) (4) (5) .
Ss was observed in 65% of randomly distributed R7s throughout development (Fig. 1C and   fig. S1 , D to G). Ss expression in adults perfectly correlated with Rh4 expression (fig. S1C) . We never observed switching of Rh expression (6) . Therefore, Ss expression is established and stably maintained throughout the lifetime of yR7 cells.
We evaluated reporter lines containing fragments of the ss gene (7). Fragment 8 (R7/R8 enhancer) in mini-gene1 induced lacZ expression in all R7s and R8s (Fig. 2, A and B) , which closely resembled expression of the Salm zinc finger transcription factor (with Salr, collectively referred to as Sal) (Fig. 2C ) that specifies R7 and R8 fate (8) . Ss expression was completely lost in sal mutants (Fig. 2D) , whereas ectopic expression of Salm in all PRs led to the activation of Ss in a random subset of outer PRs (Fig. 2E and  fig. S2A ) and expression of Mini-gene1 in outer PRs ( fig. S2B ). Thus, Sal is necessary and sufficient to activate stochastic expression of Ss in PRs. The choice to express Ss is cell autonomous because R7s and outer PRs within the same ommatidium made their decisions to express Ss independently of one another (Fig. 2E and fig. S2A ).
To identify DNA silencer elements required for stochastic Ss expression, we first defined the minimal ss DNA sequence required for stochastic ss expression. We used green fluorescent protein (GFP) from transgenes or Rh4 expression as a readout of Ss expression (Ss/Rh4), because Rh4 is always a perfect indication of Ss expression in 
